Navigation Links
Burrill & Company Reacquires Burrill Life Sciences Media Group LLC
Date:12/12/2007

SAN FRANCISCO, Dec. 12 /PRNewswire/ -- Burrill & Company announces today its reacquisition of the Burrill Life Sciences Media Group, LLC (including The Journal of Life Sciences) from Nielsen Business Media, Inc. Terms have not been disclosed.

About Burrill & Company

Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences whose principal activities are in Venture Capital, Merchant Banking and Media. The Burrill family of venture capital funds has over $950 million under management and its merchant banking business is one of the industry leaders in life sciences transactions.

Burrill publishes a range of industry intelligence reports and newsletters including: The Journal of Life Sciences, in association with the California Healthcare Institute, The Personalized Medicine Report, The Stem Cell Report, Canadian Biotech News and the Burrill Biotechnology Intelligence Report Quarterly. Its flagship publication is the "State of the Industry." The 22nd edition, entitled Biotech 2008: A Clear Vision to 2020 will be published in January 2008. These publications provide an up-to-date resource for the latest insight, intelligence and information regarding the life sciences industry.


'/>"/>
SOURCE Burrill & Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Biotech Finishes on a High in August, Burrill Report Says
2. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
3. Claim Filed Against the Company and Nine Other Defendants in the Haifa Magistrates Court
4. Cleveland-based Health Care Tech Company Within3 Names New CEO
5. Three Batesville Casket Company Production Facilities Honored for Manufacturing Expertise by National Organizations
6. iCAD to Present at William Blair & Company Small-Cap Growth Stock Conference
7. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
8. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
9. Neusoft Becomes First Global Growth Company Partner of World Economic Forum
10. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
11. Exponent to Present at the Upcoming Sidoti & Company Investor Forum and William Blair Small-Cap Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2017)... San Francisco, CA (PRWEB) , ... April 30, 2017 , ... ... Bay Area, is proud to announce an updated blog post on the continual issue ... are "too busy" to seek a second opinion before dental surgery, but this can ...
(Date:4/29/2017)... ... April 29, 2017 , ... Natural Family Planning ... observe the naturally occurring signs and symptoms of a woman's menstrual cycle. ... , Natural family planning and fertility are special interests of Dr. Bazger’s. She ...
(Date:4/29/2017)... UTAH (PRWEB) , ... April 29, 2017 , ... Phytomer ... region. As a Phytomer Account Manager, Smith’s role is to provide excellent ... brands that make up The Phytomer Group. Smith comes to Phytomer with a wealth ...
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... More than ... so what are Americans doing in their leisure time that causes hearing loss? May ... habits that may be contributing to hearing loss, as well as schedule a hearing ...
(Date:4/28/2017)... , ... April 28, 2017 , ... An April 24th article on Yahoo! ... 180 pounds with the help of a weight loss surgery. The woman, declaring “I will ... that have been left following her dramatic weight loss. Dr. Feiz & Associates notes that, ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NEW YORK , April 19, 2017 The ... anticipated to showcase a healthy CAGR during the forecast period ... product type in the global digital mobile X-Ray devices market, ... 2,000 Mn in 2017, expanding at a CAGR of 7% ... create absolute $ opportunity of more than US$ 100 Mn ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
Breaking Medicine Technology: